Bimekizumab Efficacy and Safety Versus Adalimumab in Patients With Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE). J of Skin 2021, 5 (1), s15. https://doi.org/10.25251/skin.5.supp.15.